Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Besmir Nreu

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Diabetes Research and Clinical Practice|December 25, 2019
Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase-4 inhibitors: An extensive and updated meta-analysis of randomized controlled trialsIlaria Dicembrini, Chiara Montereggi, Besmir Nreu, et al.
Diabetes Research and Clinical Practice|June 2, 2017
Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trialsMatteo Monami, Besmir Nreu, Stefania Zannoni, et al.
Diabetes Research and Clinical Practice|February 22, 2020
Cholelithiasis in patients treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trialsBesmir Nreu, Ilaria Dicembrini, Federico Tinti, et al.
Acta Diabetologica|March 26, 2015
Identification of predictors of response to basal insulin and DPP4 inhibitors in patients with type 2 diabetes failing to other therapiesMatteo Monami, Benedetta Ragghianti, Stefania Zannoni, et al.
Acta Diabetologica|September 22, 2017
Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trialsMatteo Monami, Ilaria Dicembrini, Besmir Nreu, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|August 8, 2021
Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trialsEdoardo Mannucci, Besmir Nreu, Chiara Montereggi, et al.
Diabetes, Obesity & Metabolism|March 1, 2017
Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trialsMatteo Monami, Besmir Nreu, Alessia Scatena, et al.
Diabetes Research and Clinical Practice|March 18, 2020
Immune checkpoints inhibitors and hyperglycemia: A Meta-analysis of randomized controlled trialsMatteo Monami, Lara Naletto, Besmir Nreu, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|May 26, 2020
Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trialsBesmir Nreu, Ilaria Dicembrini, Federico Tinti, et al.
Acta Diabetologica|September 20, 2017
Erratum to: Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trialsIlaria Dicembrini, Besmir Nreu, Alessia Scatena, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Diabetes Research and Clinical Practice|December 25, 2019
Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase-4 inhibitors: An extensive and updated meta-analysis of randomized controlled trialsIlaria Dicembrini, Chiara Montereggi, Besmir Nreu, et al.
Diabetes Research and Clinical Practice|June 2, 2017
Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trialsMatteo Monami, Besmir Nreu, Stefania Zannoni, et al.
Diabetes Research and Clinical Practice|February 22, 2020
Cholelithiasis in patients treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trialsBesmir Nreu, Ilaria Dicembrini, Federico Tinti, et al.
Acta Diabetologica|March 26, 2015
Identification of predictors of response to basal insulin and DPP4 inhibitors in patients with type 2 diabetes failing to other therapiesMatteo Monami, Benedetta Ragghianti, Stefania Zannoni, et al.
Acta Diabetologica|September 22, 2017
Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trialsMatteo Monami, Ilaria Dicembrini, Besmir Nreu, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|August 8, 2021
Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trialsEdoardo Mannucci, Besmir Nreu, Chiara Montereggi, et al.
Diabetes, Obesity & Metabolism|March 1, 2017
Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trialsMatteo Monami, Besmir Nreu, Alessia Scatena, et al.
Diabetes Research and Clinical Practice|March 18, 2020
Immune checkpoints inhibitors and hyperglycemia: A Meta-analysis of randomized controlled trialsMatteo Monami, Lara Naletto, Besmir Nreu, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|May 26, 2020
Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trialsBesmir Nreu, Ilaria Dicembrini, Federico Tinti, et al.
Acta Diabetologica|September 20, 2017
Erratum to: Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trialsIlaria Dicembrini, Besmir Nreu, Alessia Scatena, et al.
Pageof 3